|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| Revenues | ||||
| Products [member] | ||||
| Services [member] | ||||
| Total revenues | ||||
| Total | ||||
| Products [member] | ||||
| Services [member] | ||||
| Total total | ||||
| Gross profit | ||||
| Research and development (note 23) | ||||
| Sales and marketing (note 24) | ||||
| General and administration (note 25) | ||||
| Loss on impairment (note 9) | ||||
| Operating loss | ||||
| Loss (gain) on revaluation of warrant liabilities (note 16) | ||||
| Loss on impairment of goodwill (note 7) | ||||
| Financial income (note 27) | ||||
| Financial expenses (note 27) | ||||
| Net loss for the year from continuing operations | ||||
| Net loss for the year from discontinuing operations (note 32) | ||||
| Net loss for the year | ||||
| Less: Net loss attributable to non-controlling interests | ||||
| Net loss attributable to the Company’s shareholders | ||||
| Other comprehensive income | ||||
| Items that will not be reclassified to profit or loss: | ||||
| Adjustments arising from translating financial statements of foreign operations | ||||
| Remeasurement loss from defined benefit plans | ||||
| Other comprehensive income | ||||
| Total comprehensive loss for the year | ||||
| Less: Comprehensive loss attributable to non-controlling interests | ||||
| Comprehensive loss attributable to the Company’s shareholders | ||||
| Basic loss per share | ||||
| Basic loss per share from continuing operations | ||||
| Diluted loss per share from continuing operations | ||||
| Basic loss per share from discontinued operations | ||||
| Diluted loss per share from discontinued operations | ||||
| Basic, Weighted average number of shares outstanding | ||||
| Diluted, Weighted average number of shares outstanding | ||||
Loading...